Valuation: Axsome Therapeutics, Inc.

Market Cap 11.22B 9.75B 9.08B 8.33B 15.74B 1,071B 15.98B 107B 41.99B 533B 42.13B 41.2B 1,788B P/E 2026 *
-105x
P/E 2027 * 39.4x
Enterprise Value 11.11B 9.66B 8.99B 8.25B 15.58B 1,060B 15.82B 106B 41.58B 528B 41.71B 40.8B 1,770B EV / Sales 2026 *
11.3x
EV / Sales 2027 * 6.78x
Free-Float
84.36%
Yield 2026 *
-
Yield 2027 * -
1 day-7.10%
1 week-9.55%
1 month-10.77%
3 months+5.55%
6 months+17.27%
Current year+19.36%
1 week 217.64
Extreme 217.64
242.1
1 month 217.64
Extreme 217.64
252.6
Current year 152.28
Extreme 152.28
260.19
1 year 96.09
Extreme 96.09
260.19
3 years 55.02
Extreme 55.02
260.19
5 years 19.38
Extreme 19.38
260.19
10 years 1.94
Extreme 1.94
260.19
Manager TitleAgeSince
Chief Executive Officer 57 2012-01-11
Director of Finance/CFO 51 2018-05-15
Chief Operating Officer 42 2014-03-31
Director TitleAgeSince
Chairman 57 2012-01-11
Director/Board Member 64 2014-11-30
Director/Board Member 58 2014-11-30
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Fiscal year

Chief Executive Officer

148,998 0.2895%
6/5/26 Free

Director

1,721 0.0033%
4/22/26 Fiscal year

Executive/Senior Manager

22,500 0.0440%
Change 5-day change 1-year change 3-year change Capi.($)
-7.10%-9.55%+111.60%+197.56% 11.22B
+3.29%+16.25%+36.46%+4.17% 76.15B
+0.13%-8.50%+21.80%+183.82% 48.89B
-2.75%+48.50%+48.50%+48.50% 47.83B
+1.01%+6.80%-53.08%-53.45% 41.37B
-2.40%+0.38%+53.81%-25.27% 29.99B
-2.82%+1.57%+58.12%+81.97% 24.23B
-5.35%+1.39%+98.59%-50.26% 21.89B
-0.81%-3.75%-7.43%+162.20% 19.25B
-6.80%-3.41%+66.12%+119.06% 17.14B
Average -2.08%+0.38%+43.45%+66.83% 33.79B
Weighted average by Cap. -0.68%+2.56%+33.70%+50.07%

Financials

2026 *2027 *
Net sales 979M 851M 792M 727M 1.37B 93.46B 1.39B 9.34B 3.66B 46.53B 3.68B 3.6B 156B 1.6B 1.39B 1.29B 1.19B 2.24B 152B 2.27B 15.23B 5.98B 75.87B 6B 5.86B 254B
Net income -108M -93.99M -87.48M -80.32M -152M -10.32B -154M -1.03B -405M -5.14B -406M -397M -17.23B 308M 267M 249M 229M 432M 29.37B 438M 2.93B 1.15B 14.62B 1.16B 1.13B 49.03B
Net Debt -111M -96.23M -89.57M -82.23M -155M -10.57B -158M -1.06B -414M -5.26B -416M -407M -17.64B -394M -342M -319M -293M -552M -37.59B -561M -3.76B -1.47B -18.72B -1.48B -1.45B -62.75B
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Employees
1,220
Date Price Change Volume
26-08-03 $216.25 -0.80% 29,514
26-07-31 $217.99 -7.10% 782,168
26-07-30 $234.64 +3.17% 714,361
26-07-29 $227.42 -2.89% 523,066
26-07-28 $234.20 -1.75% 404,143
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
217.99USD
Average target price
282.32USD
Spread / Average Target
+29.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXSM Stock